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We have analyzed the expression of the intracellular marker protein neuron specific enolase (NSE), synaptophysin (SYN) and of the cell surface 
marker NCAM (neural cell adhesion molecule) in both normal human hypophysis and in pituitary adenomas in order to explore their potential 
use as diagnostic tools. All adenomas (4 prolactinomas, 3 growth hormone (GH) producing adenomas and 4 inactive adenomas) showed SYN 
and NSE immunoreactivity on tissue sections and this was confirmed by immunoblots. NCAM 140 (an isoform of NCAM with molecular mass 
140 kDa) was detected by immunoblotting in normal human adenohypophysis, in all GH adenomas, and in three out of four inactive adenomas, 
but not in prolactinomas. Using highly sensitive techniques, NCAM immunoreactivity was observed by electron microscopy in all adenomas. These 
data indicate that NCAM 140 is a constituent of the cell surface of endocrine cells in both normal human adenohypophysis and its tumors. Since 
prolactinomas express very low levels of NCAM 140 compared to other hypophyseal tumors its virtual absence could be used for differential diagno- 
sis. A combined analysis of NCAM, SYN and NSE could be useful to characterize inactive adenomas which are not immunoreactive for pituitary 
hormones and which may contain no or only low levels of the alpha chain of the glycoprotein hormones. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Though widely dispersed in different tissues 
throughout the body, endocrine cells have many pro- 
perties in common [l], some of which are also shared 
with cells of the nervous system. Thus neuron specific 
enolase (NSE) first recognized in the central nervous 
system has since become a ‘classical’ marker for en- 
docrine cells [2]. More recently, other intracellular pro- 
teins including synaptophysin (SYN), a constituent of 
secretory vesicles, and neural cell adhesion molecule 
(NCAM), a family of molecules which have been im- 
plicated in intercellular adhesion and neural 
histogenesis, have been shown to be shared by both 
neural and endocrine cells [3-61. The molecular and 
cell biology of these markers is well documented 
[7-lo]. The analysis of these more recently discovered 
proteins in human pituitary tumors represents an essen- 
tial step in assessing potential applications in clinical 
diagnosis. In this study we report immunocytochemical 
and immunological data on NSE-, SYN- and NCAM- 
expression in various clinically and histochemically 
defined human adenomas which demonstrate the value 
of these molecules as diagnostic markers. 
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2.1. Tissues 
11 surgically removed pituitary adenomas (prolactinoma, GH 
adenoma, hormonally inactive adenoma), 1 normal neurohypophysis 
and 2 normal adenohypophyses were investigated. For elec- 
trophoresis and immunoblotting the tissues were frozen in 0.5 M HCl 
immediately after excision. For immunocytochemical nalysis of 
NCAM small tissue pieces were fixed immediately by immersion in 
freshly prepared phosphate-buffered paraformaldehyde (0.1 M, pH 
7.2, 4%) for 2-3 h at room temperature. 
2.2. Immunocytochemistry 
NCAM was detected by electron microscopy using the pre- 
embedding streptavidin-biotin method [ 1 l] or the indirect method as 
described previously [5,6,12]. Biotinylated donkey anti-rabbit im- 
munoglobulin and peroxidase-streptavidin, obtained from Amer- 
sham, were used at dilutions recommended by the manufacturers. A
polyclonal antibody (kindly provided by Dr G. Rougon, Marseille, 
France) directed against the undecapeptide present at the aminoter- 
minal of the mouse NCAM (dilution 1: 1000 or 1:ZOOO) was 
employed [ 131. 
For detection of SYN, NSE, pituitary hormones and the alpha 
chain of the glycoprotein hormones the surgically resected adenomas 
were fixed in phosphate-buffered formaldehyde (4%) and embedded 
in paraffin. The de-paraffinized sections were incubated with a 
polyclonal rabbit serum directed against rat synaptophysin (SYN, 
dilution 1: loo0, kindly provided by Dr R. Jahn, Munich, FRG) and 
human neuron-specific enolase (NSE, dilution 1: 1000; Dakopatts, 
Copenhagen, Denmark). The immunoreaction was visualized by the 
indirect peroxidase-anti-peroxidase method [14] using reagents ob- 
tained from Dakopatts (Copenhagen, Denmark). Im- 
munocytochemical detection of prolactin (PRL), growth hormone 
(GH), corticotropin (ACTH) and alpha chain was carried out as 
described recently [15]. 
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2.3. Electrophoresis and immunoblotting 3. RESULTS AND DISCUSSION 
Tissues were cut into small pieces and lysed in extraction medium 
(62.5 mM Tris, 2% SDS, 10% sucrose, pH 6.8) by sonication. The 
lysate was boiled for 5 min and centrifuged at 10000 x g. SDS-PAGE 
(7.5%) under reducing conditions (So-150 pg of protein/lane) and 
immunoblotting were performed as previously described [16]. Blots 
were incubated with antibodies directed against NCAM (dilution 
1: lOOO), SYN (dilution 1: 10000) and NSE (dilution 1: 3000). Since 
only small amounts of tissue were available the same nitrocellulose 
strips were first incubated with anti-NCAM antibody and then with 
anti-SYN antibody or anti-NSE antibody. Binding of antibodies was 
detected by iodinated protein A [16]. 
Prolactinomas, GH adenomas and hormonally inac- 
tive adenomas comprise about 90% of the pituitary 
tumors in man [ 15). We have investigated the 
characteristic onstituents of these frequent adenomas 
with different immunological techniques. The clinical 
features of the patients from which the tumors were 
removed by transphenoidal surgery (except case 5 in 
which the tumor was removed transcranially) are listed 
in Table I. 
Table I 
Clinical features of the patients suffering from pituitary tumors 
Diagnosis Case Sex and Symptoms MRVCT scanElevated hormone 
No. age (years) appearance values 
Prolactinoma 1 M 53 visual failure SSE 
PSE PRL 1157 pg/l 
2 M 55 headache, gynecomastia ISE PRL 916 /g/l 
3 M 26 headache, visual failure SSE PRL 456 pg/l 
4 M 31 visual failure, hypogonadism SSE 
PSE PRL 10440 fig/l 
GH-adenoma 5 M 38 acromegaly, impotence PSE GH 53 ,&l 
6 M 49 acromegaly, carpal 
tunnel syndrome MI GH 14&l 
7 F 53 acromegaly, hypertension PSE GH 14,&l 
Hormonally inactive 
adenoma 8 M 57 hypogonadism, visual 
failure, fatigue SSE - 
9 F 49 headache MA _ 
10 M 52 visual failure, decreased 
libido SSE - 
11 M 30 visual failure, headache, 
impotence SSE PRL 11.8rg/l 
CT, computed tomography; MRI, magnetic resonance imaging; M, male; F, female; PRL, prolactin; 
GH, growth hormone; SSE, tumor with suprasellar extension; PSE, tumor with parasellar extension; 
ISE, tumor with infrasellar extension; MI, intrasellar microadenoma; MA, intrasellar macroadenoma 
Table II 
Immunocytochemical nd immunological characterization of the pituitary tumors 
Clinical diagnoses Case Immunocytochemical nalysis Immunoblotting 
Hormones Markers SYN NSE NCAMl40 
Alpha ACTH GH PRL SYN NSE 
Prolactinomas 1 nd + + (+) + (+) - 
2 - - - + + + + - 
3 nd + + (1) + + - 
4 - S S + + + + + _ 
GH adenomas 5 + - + - + (+) + + 
6 nd _ + _ + + + + (f) 
7 nd S + nd + + + + f 
Hormonally inactive 
adenomas 8 _ _ _ _ + + + + + 
9 s - - - + + + _ 
10 + - - - t + (1, + + 
11 - - - - + t + + t 
+ , positive finding; - , negative finding; nd, not determined; s, some cells stain; (+), weak staining or faint 
band in immunoblots 
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Recently we discovered that NCAM, originally 
thought to be confined in adults to the nervous system 
is present in rat endocrine cells including the 
adenohypophysis [5,6]. The present study investigates 
whether human pituitary tumors also contain such 
molecules, and whether they could be employed as 
general markers of endocrine cells like NSE. As shown 
in Table II the prolactinomas and GH adenomas’ 
analyzed here contain NSE in addition to certain hor- 
mones. It is also present in the heterogeneous group of 
hormonally inactive adenomas . 
Synaptophysin (SYN) first discovered in 1977 and 
named synaptin [17] and subsequently studied in- 
Fig. 1. Cells of a hormonally inactive adenoma (Case 9) 
immunostained for SYN (a) and NSE (b). Immunoperoxidase 
reaction products are localized intracellularly. Bars = 20 pm. 
dependently under the names of P38 [3,8] and synap- 
tophysin [4,7,9] has been reported to occur in pituitary 
tumors which were not characterized further [18]. Us- 
ing both immunocytochemistry and immunoblot 
analysis SYN was unambiguously demonstrated in all 
the types of pituitary tumors classified here (Table II). 
We may thus conclude that SYN, like NSE, can be used 
as a general marker for pituitary tumors. In particular 
the inactive adenomas, which are not immunoreactive 
for pituitary hormones and may show no or only weak 
staining for the alpha chain of the glycoprotein hor- 
mones (see cases 8, 9 and 11, Table II) do express NSE 
and SYN. Thus NSE and SYN are valuable markers for 
identifying these neoplasms by immunological (Table 
II) and immunocytochemical techniques (see Fig. 1). 
NCAM 140 is the only NCAM isoform detected in 
the normal human adenohypophysis, while the three 
isoforms of this family typical of nervous tissue pro- 
teins (NCAM 120, NCAM 140, NCAM 180) are present 
in the neural lobe of the hypophysis (Fig. 2). This dif- 
ference between neurohypophysis and 
adenohypophysis agrees with data obtained in the rat 
pituitary [6]. NCAM could not be detected in prolac- 
tinomas by immunoblotting but NCAM 140 was detec- 
table using such techniques in GH adenomas and also 
in three out of four hormonally inactive adenomas (see 
Fig. 2 and Table II). The apparent absence of NCAM 
in the prolactinomas reflects the limits of detection of 
these proteins by this method, since, by using sensitive 
immunocytochemical procedures, NCAM could be 
detected even in prolactinomas at the electron 
microscopical evel (Fig. 3). Prolactinomas stained less 
intensely but the distribution of the immunoreaction 
product in prolactinomas was indistinguishable from 
that seen in GH adenomas which contain sufficient 
NCAM 140 to be easily detected on immunoblots 
(Fig. 2 and Table II). 
NCAM 140 was not detectable by immunoblotting in 
one hormonally inactive tumor (case 9, see Table II). It 
180 
140 
120 
Fig. 2. Immunological identification of NCAM in human 
neurohypophysis (lane l), adenohypophysis (lane 2), and different 
pituitary adenomas (GH adenoma (case 5), lane 3; hormonally 
inactive adenoma (case 8), lane 4; inactive adenoma containing the 
alpha chain (case lo), lane 5; prolactinoma (case I), lane 6). The 
molecular masses of the NCAM isoforms are indicated. 
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Fig. 3. Electron micrograph of prolactinoma (a, case 2) and GH adenoma (b, case 7) cells labeted for NCAM. The cell surface molecule is loca lized 
over the entire plasma membrane. No detectable levels of the antigen are found intracellulariy. Section not counterstained (bars = 1 .UI n). 
is po$ rsible that this adenoma is in fact a prolactinoma 
in or igin producing low levels of prolactin (which are 
undel :ectable by immunoc~o~hemistry) but which, 
howe ver, might be detectable with very sensitive 
hybridization techniques with PRL mRNA probes [ 
Both the histological features of this tumor (‘burnt 
tumor’) and the apparent absence of NCAM 140 on 
munoblots accord with this interpretation. 
191. 
out 
im- 
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It is interesting to note that most hormonally inactive 
pituitary tumors also stain for chromogranin A (CGA) 
[20]. While prolactinomas do not appear to contain 
CGA, GH adenomas have been shown to express CGA 
[20] and more recently CGA mRNA has been 
demonstrated in GH adenomas [21]. This suggests that 
CGA is differentially expressed by pituitary adenomas 
in a similar way as NCAM 140. 
In summary, immunological analysis of pituitary 
adenomas for NSE and SYN permits unambiguous 
identification of the endocrine nature of the tumor 
tissue. This is particularly important in about 20% of 
all adenomas which are hormonally inactive [15] and 
for which therefore hormones cannot be used as 
markers. Hormones, however, are valuable tools for 
the identification of both GH adenomas and prolac- 
tinomas. These adenomas can also be distinguished by 
their levels of CGA and NCAM 140. A practical 
feature of CGA is that it is a secretory product and thus 
may provide a functional marker for GH adenomas or 
for tumors that do not express hormones (inactive 
adenomas). Therefore CGA could be employed for 
these adenomas clinically as a serum marker, in a 
similar way as for other endocrine neoplasms [22,23]. 
We have demonstrated here that NCAM could also 
be used for immunohistochemical and im- 
munochemical differential tumor diagnosis. A unique 
advantage of NCAM compared with the other in- 
tracellular markers such as NSE, SYN or CGA con- 
cerns its accessibility as a surface molecule. We suggest 
that antibodies against NCAM could be used for im- 
munoscintigraphy, radiotherapy or targeting of drugs 
to adenoma cells. In conclusion, this investigation of 
the differential expression of NCAM in different 
pituitary tumors suggest that this marker may be added 
to the range of markers currently used for tumor 
diagnosis and in addition, may provide a possible route 
for their treatment. In this context it is interesting to 
note that NCAM has been recently detected in another 
frequent human endocrine tumor, the small cell lung 
carcinoma [24-271. 
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